Company Encyclopedia
View More
name
IM Cannabis
IMCC.US
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands. The company serves medical patients.
4.346 T
IMCC.USMarket value -Rank by Market Cap -/-

Financial Score

18/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking162/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-94.71%E
    • Profit Margin-8.96%D
    • Gross Margin19.72%D
  • Growth ScoreC
    • Revenue YoY-2.32%D
    • Net Profit YoY65.01%B
    • Total Assets YoY-3.56%D
    • Net Assets YoY-0.76%D
  • Cash ScoreD
    • Cash Flow Margin-1115.46%E
    • OCF YoY-2.32%D
  • Operating ScoreA
    • Turnover1.18A
  • Debt ScoreE
    • Gearing Ratio90.29%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    IM Cannabis Corp. Cancels December 2025 Special Meeting

    IM Cannabis Corp. has canceled its Special Meeting of Security Holders scheduled for December 29, 2025. The cancellation affects various record dates, including the notice of meeting, voting, and beneficial ownership determination. Analysts rate IMCC stock as a Sell with a $1.00 price target, citing poor financial performance, ongoing losses, and negative cash flows. The company operates in the cannabis industry, focusing on production and distribution, and is based in Kibbutz Glil Yam, Israel.

    Tip Ranks·
    US
    IMCC
    +34.20%
    Tip Ranks·
    US
    IMCC
    +34.20%

    IM Cannabis Corp. publishes MD&A report for Q3 2025

    IM Cannabis Corp. released its Q3 2025 MD&A report, detailing financial and operational results. The company emphasized its focus on international medical cannabis operations, with shares now trading solely on Nasdaq after delisting from the Canadian Securities Exchange. Efforts continue in expanding market presence and product offerings, with ongoing activities in Israel and Europe. The report was published on November 13, 2025.

    Reuters·
    US
    IMCC
    +34.20%
    Reuters·
    US
    IMCC
    +34.20%

    IM Cannabis Corp. reports Q3 revenue of $13.9 million and net loss of $3.9 million

    IM Cannabis Corp. reported Q3 2025 revenue of $13.9 million, unchanged from Q3 2024. Gross profit fell 13% to $2.7 million, with a net loss of $3.9 million due to a $3.1 million impairment. Excluding this, net loss was $0.8 million. Adjusted EBITDA loss was $0.6 million. Regulatory changes in Germany may impact sales, and the company is reviewing new business activities.

    Reuters·
    US
    IMCC
    +34.20%
    Reuters·
    US
    IMCC
    +34.20%

    NICE Limited to Announce Third Quarter 2025 Results

    NICE Limited will announce its third quarter 2025 results on November 13, 2025, before the NASDAQ opens. A conference call with management will follow the announcement, accessible via webcast on the Company’s website. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

    Reuters·
    US
    NICE
    -12.58%
    Reuters·
    US
    NICE
    -12.58%

    UiPath Inc. to Release Third Quarter Fiscal 2026 Financial Results

    UiPath Inc. will announce its third quarter fiscal 2026 financial results on December 3, 2025. The results will be available on the investor relations website, followed by a conference call and webcast at 5:00 pm ET on the same day.

    Reuters·
    US
    PATH
    +1.63%
    Reuters·
    US
    PATH
    +1.63%